Durham, NC, United States of America

Andy Ommen


Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 89(Granted Patents)


Company Filing History:


Years Active: 2010

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Andy Ommen

Introduction

Andy Ommen is a notable inventor based in Durham, NC (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds for cancer treatment. His work is characterized by a focus on innovative chemical formulations that have the potential to impact patient care.

Latest Patents

Ommen holds a patent for "Quinazoline derivatives for the treatment of cancer." This invention is directed toward compounds and pharmaceutically acceptable salts of a specific formula. The compounds are designed to be useful in treating diseases and conditions related to cell proliferation, such as cancer. Additionally, the invention includes pharmaceutical compositions comprising these compounds, showcasing Ommen's commitment to advancing medical science.

Career Highlights

Andy Ommen is currently associated with Serenex, Inc., where he continues to work on groundbreaking research. His career is marked by a dedication to developing innovative solutions that address critical health challenges. With a focus on cancer treatment, Ommen's work exemplifies the intersection of science and compassion.

Collaborations

Throughout his career, Ommen has collaborated with esteemed colleagues, including Kenneth He Huang and James Marvin Veal. These partnerships have fostered an environment of innovation and creativity, allowing for the exchange of ideas and expertise in the field of pharmaceuticals.

Conclusion

In summary, Andy Ommen's contributions to the field of cancer treatment through his innovative patents and collaborations highlight his role as a significant inventor. His work at Serenex, Inc. continues to pave the way for advancements in medical therapies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…